Silence Therapeutics more than doubles on $1.3 bln Merck KGaA buyout deal
Mon 14:01
BUZZ-Silence Therapeutics more than doubles on $1.3 bln Merck KGaA buyout deal ** U.S.-listed shares of Silence Therapeutics SLNCF.PK, SLN.O rise 126% to $19.62 premarket
** Merck KGaA MRCG.DE to acquire Silence Therapeutics in an all-cash deal valued at about $1.3 billion
** Merck will pay $20 per share for Silence, representing a premium of 130% to the stock's last close
** The buyout gives Merck ownership of Divesiran, a late-stage trial ready siRNA therapy for polycythemia vera, a rare blood cancer
** The companies expect the deal to close in Q1 2027
** As of last close, SLN up 42% YTD
(Reporting by Kamal Choudhury in Bengaluru)